Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
CES Odontología
versión impresa ISSN 0120-971X
Resumen
VILELA-CARVALHO, Lidia Nunes; TUANY-DUARTE, Nathália; ANDRADE-FIGUEIREDO, Marília y LOPEZ-ORTEGA, Karem. Medication-Related Osteonecrosis of the Jaw: Diagnosis, treatment and prevention. CES odontol. [online]. 2018, vol.31, n.2, pp.48-63. ISSN 0120-971X. https://doi.org/10.21615/cesodon.31.2.5.
Osteonecrosis of the jaws is a bone alteration that can be induced using drugs indicated for the treatment of patients with osteoporosis and malignant tumors. Initially it was believed to be associated only with the use of bisphosphonates, currently it is known that it is also linked to the use of other antiresorptive (denosumab) and antiangiogenic (bevacizumab). It is not known what the development mechanism is and there is still no single defined treatment protocol, but there are several papers being published on the topic. With the increasing number of cases reported, it is extremely important that the health professional can diagnose, identify the risks and treat this condition.
Palabras clave : Osteonecrosis of the jaws; Bisphosphonates; Denosumab; Bevacizumab.